SUMITOMO PHARMA CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 410 JPY | +2.50% |
|
+5.40% | -12.02% |
| Apr. 22 | Lull in Geopolitical Tensions Lifts Asian Stock Markets | MT |
| Apr. 17 | Jefferies Adjusts Sumitomo Pharma’s Price Target to 420 Yen From 520 Yen, Keeps at Hold | MT |
Valuation
| Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,087,401 | 557,406 | 765,586 | 479,930 | 321,807 | 162,889 | - | - |
| Enterprise Value (EV) 1 | 937,295 | 724,961 | 816,227 | 545,994 | 524,701 | 455,213 | 465,681 | 471,758 |
| P/E ratio | 22.4 x | 13.7 x | 13.6 x | 8.51 x | -4.32 x | -0.82 x | -3.34 x | -8.3 x |
| Yield | 1.02% | 2% | 1.45% | 2.32% | 2.59% | - | - | - |
| Capitalization / Revenue | 2.37 x | 1.15 x | 1.48 x | 0.86 x | 0.58 x | 0.52 x | 0.47 x | 0.45 x |
| EV / Revenue | 2.04 x | 1.5 x | 1.58 x | 0.97 x | 0.94 x | 1.44 x | 1.33 x | 1.31 x |
| EV / EBITDA | 13 x | 7.21 x | 8.69 x | 5.54 x | 9.11 x | -2.76 x | 20.2 x | 28.6 x |
| EV / FCF | 23.8 x | -2.72 x | 5.65 x | 42.1 x | -13 x | -3.58 x | -17.6 x | -233 x |
| FCF Yield | 4.21% | -36.8% | 17.7% | 2.37% | -7.72% | -27.9% | -5.69% | -0.43% |
| Price to Book | 2.18 x | 1.05 x | 1.32 x | 0.79 x | 0.79 x | 0.72 x | 0.95 x | 1.09 x |
| Nbr of stocks (in thousands) | 397,297 | 397,295 | 397,294 | 397,293 | 397,292 | 397,291 | - | - |
| Reference price 2 | 2,737 | 1,403 | 1,927 | 1,208 | 810.0 | 410.0 | 410.0 | 410.0 |
| Announcement Date | 5/10/19 | 5/13/20 | 5/12/21 | 5/13/22 | 5/15/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 459,267 | 482,732 | 515,952 | 560,035 | 555,544 | 316,260 | 349,728 | 359,056 |
| EBITDA 1 | 71,860 | 100,604 | 93,897 | 98,582 | 57,627 | -165,072 | 23,054 | 16,493 |
| EBIT 1 | 57,884 | 83,239 | 71,224 | 60,234 | -76,979 | -200,985 | -44,049 | -15,766 |
| Operating Margin | 12.6% | 17.24% | 13.8% | 10.76% | -13.86% | -63.55% | -12.6% | -4.39% |
| Earnings before Tax (EBT) 1 | 65,046 | 83,947 | 77,851 | 82,961 | -47,920 | -197,567 | -47,130 | -18,631 |
| Net income 1 | 48,627 | 40,753 | 56,219 | 56,413 | -74,512 | -198,180 | -48,695 | -19,626 |
| Net margin | 10.59% | 8.44% | 10.9% | 10.07% | -13.41% | -62.66% | -13.92% | -5.47% |
| EPS 2 | 122.4 | 102.6 | 141.5 | 142.0 | -187.6 | -498.8 | -122.6 | -49.40 |
| Free Cash Flow 1 | 39,446 | -266,556 | 144,476 | 12,961 | -40,482 | -127,120 | -26,484 | -2,027 |
| FCF margin | 8.59% | -55.22% | 28% | 2.31% | -7.29% | -40.19% | -7.57% | -0.56% |
| FCF Conversion (EBITDA) | 54.89% | - | 153.87% | 13.15% | - | - | - | - |
| FCF Conversion (Net income) | 81.12% | - | 256.99% | 22.98% | - | - | - | - |
| Dividend per Share 2 | 28.00 | 28.00 | 28.00 | 28.00 | 21.00 | - | - | - |
| Announcement Date | 5/10/19 | 5/13/20 | 5/12/21 | 5/13/22 | 5/15/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2020 S2 | 2021 S1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 S1 | 2025 Q3 | 2025 Q4 | 2026 S1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 230,603 | 252,129 | 261,498 | 162,534 | 293,730 | 138,342 | 127,963 | 159,876 | 159,400 | 319,300 | 140,976 | - | 75,700 | 76,942 | 152,642 | 82,386 | 79,948 | 81,269 | - | 166,420 | - | - | 177,456 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -21,646 | - | - | - | - | - | - | - |
| EBIT 1 | 66,835 | 16,404 | 47,539 | 39,266 | 47,572 | 10,656 | 2,006 | 14,614 | -43,500 | -28,900 | 11,138 | - | -51,600 | -34,898 | -86,498 | -31,247 | -51,031 | -18,664 | - | -36,422 | - | - | -9,217 |
| Operating Margin | 28.98% | 6.51% | 18.18% | 24.16% | 16.2% | 7.7% | 1.57% | 9.14% | -27.29% | -9.05% | 7.9% | - | -68.16% | -45.36% | -56.67% | -37.93% | -63.83% | -22.97% | - | -21.89% | - | - | -5.19% |
| Earnings before Tax (EBT) 1 | 64,147 | 19,800 | 43,654 | 41,309 | 49,266 | 16,317 | 17,378 | 46,610 | -25,610 | 21,000 | -18,842 | - | -31,100 | -25,027 | -56,127 | -49,064 | -75,454 | -18,754 | - | -36,602 | - | - | -9,397 |
| Net income 1 | 30,330 | 10,423 | 37,297 | 31,650 | 36,450 | 9,909 | 10,054 | 31,108 | -38,400 | -7,300 | -11,219 | - | -38,900 | -28,841 | -67,741 | -49,967 | -64,418 | -14,065 | - | -27,452 | - | - | -7,048 |
| Net margin | 13.15% | 4.13% | 14.26% | 19.47% | 12.41% | 7.16% | 7.86% | 19.46% | -24.09% | -2.29% | -7.96% | - | -51.39% | -37.48% | -44.38% | -60.65% | -80.58% | -17.31% | - | -16.5% | - | - | -3.97% |
| EPS 2 | 76.34 | - | 93.88 | 79.66 | 91.75 | 24.94 | 25.30 | 78.30 | -96.63 | -18.33 | -28.24 | -141.0 | -97.82 | -72.69 | -170.5 | -125.8 | -266.3 | -35.40 | - | -69.10 | - | - | -17.70 |
| Dividend per Share 2 | 14.00 | - | 14.00 | - | 14.00 | - | - | - | - | 14.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/28/19 | 5/13/20 | 10/28/20 | 10/27/21 | 10/27/21 | 1/31/22 | 5/13/22 | 7/29/22 | 10/31/22 | 10/31/22 | 1/31/23 | 5/15/23 | 7/31/23 | 10/31/23 | 10/31/23 | 1/31/24 | - | - | - | - | - | - | - |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 167,555 | 50,641 | 66,064 | 202,894 | 292,323 | 302,792 | 308,869 |
| Net Cash position 1 | 150,106 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 1.665 x | 0.5393 x | 0.6701 x | 3.521 x | -1.771 x | 13.13 x | 18.73 x |
| Free Cash Flow 1 | 39,446 | -266,556 | 144,476 | 12,961 | -40,482 | -127,121 | -26,484 | -2,027 |
| ROE (net income / shareholders' equity) | 10.2% | 7.9% | 10.1% | 9.5% | -14.7% | -59.2% | -18.7% | -6.58% |
| ROA (Net income/ Total Assets) | 7.91% | 8.04% | 4.38% | 6.34% | -3.92% | -19.9% | -2.96% | -2.79% |
| Assets 1 | 614,659 | 506,723 | 1,283,539 | 889,478 | 1,899,145 | 994,132 | 1,645,849 | 702,755 |
| Book Value Per Share 2 | 1,254 | 1,333 | 1,461 | 1,530 | 1,024 | 571.0 | 432.0 | 378.0 |
| Cash Flow per Share 2 | 158.0 | 146.0 | 199.0 | 239.0 | -83.70 | -302.0 | -209.0 | 71.90 |
| Capex 1 | 9,265 | 7,722 | 6,048 | 7,347 | 14,600 | 14,080 | 12,280 | 12,280 |
| Capex / Sales | 2.02% | 1.6% | 1.17% | 1.31% | 2.63% | 4.45% | 3.51% | 3.42% |
| Announcement Date | 5/10/19 | 5/13/20 | 5/12/21 | 5/13/22 | 5/15/23 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
410
JPY
Average target price
333.8
JPY
Spread / Average Target
-18.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.02% | 1.03B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4506 Stock
- Financials Sumitomo Pharma Co., Ltd.
